I am committed to steering the next wave of healthcare breakthroughs, ensuring they reach their full potential and deliver real-world benefits.Steering MEDIPOST, Inc., our team is globalizing CARTISTEM®, our company's flagship product and the world's first allogeneic stem cell therapy for knee osteoarthritis (OA), approved in Korea in 2012 and used to treat over 30,000 patients. Our expertise in orthobiologics and cell therapy is channeled into advancing CARTISTEM®, prepping for a pivotal Phase III study. As a leader in regenerative medicine, the mission is clear: to transform the treatment landscape of inflammation-driven degenerative diseases.Serving on the board of OmniaBio, we are setting a new standard CGT manufacting in Canada driving forward the advancements in immunotherapy and iPSC technologies. Concurrently, my role at Digitalis Commons as an Expert-in-Residence leverages R&D acumen to mentor health technology innovators. This symbiosis of business strategy and scientific insight is vital in translating cutting-edge research into tangible health solutions.And finally at X-Factor Capital, the focus is on strategic growth and development of early-stage companies in the regenerative medicine and cell therapy sectors. With over a decade of experience, my role involves driving these organizations from their nascent stages to periods of significant expansion. Harnessing insights from business, finance, and science, the goal is to propel innovative therapies into their high-growth phases.